Adagene and Third Arc Bio collaborate on masked CD3 T cell engagers
Under a new agreement, Third Arc Bio will utilise Adagene’s SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumour associated antigens. In return, Third Arc Bio will receive rights to research, develop and commercialise two candidate molecules worldwide. Adagene will receive… Read More